This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0171U for the MyMRD® NGS Panel test from the Laboratory for Personalized Molecular Medicine, which uses a blood or bone marrow specimen to pinpoint minimal residual disease (MRD) using next–generation sequencing (NGS) to target mutation hotspots in 23 genes that may drive myeloid malignancies, including acute myeloid leukemia (AML), myeloproliferative neoplasms(MPN), and myelodysplastic syndromes (MDS).
For clinical responsibility, terminology, tips and additional info
start codify free trial.